Fujifilm Starts a U.S. Phase I Clinical Trial of Anti-Cancer Agent “FF-10850” on Advanced Solid Tumors


Clinical Development of a Novel Liposome Drug with Mechanism of Selective Delivery of Anti-Cancer Agent to Tumors

FUJIFILM Corporation (President: Kenji Sukeno) announced the start of a U.S. Phase I clinical trial of FF-10850, an anti-cancer agent targeting advanced solid tumors. FF-10850 is a liposome-based agent in which topotecan*, an approved anti-cancer agent, has been encapsulated in the newly developed liposome. The study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FF-10850.

As a drug delivery system (DDS), liposomes are artificially constructed vesicles made from the organic phospholipids which make up cellular membranes and biomembranes. Liposomes can deliver the required amount of a drug to the specific area of the body on predetermined schedule. Anti-cancer agents can act on normal cells, in addition to cancer which can induce strong adverse reactions. By encapsulating a drug in liposomes it is expected to selectively deliver the drug to cancer cells, suppress adverse reactions, and improve pharmacological efficacy.